Project #1169

Teach Traditional Ethiopian Midwives to Save Lives

by VSI, Venture Strategies Innovations

In the spring of 2006, traditional midwives from the rural Tigray region of Ethiopia were trained to administer misoprostol to women after delivery during home births. The off-patent drug is used for controlling postpartum hemorrhage, the leading cause of maternal death. By September 2006, the study had been implemented in over 100 births. Early results show that traditional midwives are capable of safely and effectively providing this life-saving drug to their clients. The Ethiopian doctor heading the study recently visited one of the villages where the drug was in use. As he arrived, he was surprised to be surrounded by women singing and dancing, a spontaneous welcome party. "We are so grateful to have this drug at home," they sang. Venture Strategies is proud to be a part of this demonstration project with the Ethiopian Ministry of Health.

Ethiopia has taken an historic step to become the second country in the world to approve an old drug, misoprostol, for a new use, controlling postpartum hemorrhage. Postpartum hemorrhage, life-threatening bleeding following childbirth, is the leading cause of maternal deaths worldwide.

Our non-profit organization, Venture Strategies for Health and Development, worked with UC Berkeley's School of Public Health to help the Ethiopian Ministry of Health obtain this regulatory approval. Now the drug will be imported and made available for saving the lives of the approximately 8,200 Ethiopian women who die each year from this condition.

Our team helped Nigeria become the first country to obtain a similar regulatory approval in January.

Venture Strategies for Health and Development and UC Berkeley will continue to assist the Ethiopian Ministry of Health develop their rollout of misoprostol throughout the country with specific focus on distribution to rural areas.

Our nonprofit organization works to improve the health of low income people in resource-poor settings, by making use of existing market forces around the world. We are providing policy, medical, and distribution strategy support to several countries evaluating the introduction of misoprostol to save mothers' lives. By facilitating South-South trade, we help countries obtain high-quality low-cost health products from generic manufacturers, at their request.

If you would like to read more about our misoprostol projects and related publications, we invite you to see our web site.


About Project Reports

Project Reports on GlobalGiving are posted directly to by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.

If you donate to this project or have donated to this project, you will get an e-mail when this project posts a report. You can also subscribe for reports via e-mail without donating.

Get Reports via Email

We'll only email you new reports and updates about this project.

Organization Information

VSI, Venture Strategies Innovations

Location: Irvine, California - USA
Website: http:/​/​
VSI, Venture Strategies Innovations
Project Leader:
Allison Boiles
Communications Specialist
Anaheim, CA United States

Funded Project!

Thanks to 123 donors like you, a total of $10,373 was raised for this project on GlobalGiving. Combined with other sources of funding, this project raised enough money to fund the outlined activities and is no longer accepting donations.

Still want to help?

Find another project in Ethiopia or in Health that needs your help.
Find a Project

Learn more about GlobalGiving

Teenage Science Students
Vetting +
Due Diligence


Woman Holding a Gift Card
Gift Cards

Young Girl with a Bicycle

Sign up for the GlobalGiving Newsletter

WARNING: Javascript is currently disabled or is not available in your browser. GlobalGiving makes extensive use of Javascript and will not function properly with Javascript disabled. Please enable Javascript and refresh this page.